US Doctors Could Prescribe MDMA in 2024 MDMA is a

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
249
US Doctors Could Prescribe MDMA in 2024

MDMA is a stimulant drug that causes hallucinations. Researchers have found that the drug, which is also known as ecstasy or molly, may be useful in the treatment of a range of mental health conditions, including anxiety.

A recently conducted medical trial also found that the drug, which is popular in rave culture, could effectively treat post-traumatic stress disorder. Post-traumatic stress disorder is a mental health condition that’s usually triggered when an individual witnesses or experiences a traumatic event. Symptoms may include nightmares, flashbacks and severe anxiety, among other things.

The trial was carried out by Multidisciplinary Association for Psychedelic Studies (MAPS), which is a not-for-profit organization that’s focused on raising awareness of psychedelic substances. For their study, the researchers recruited 90 participants suffering from severe post-traumatic disorder. Each of these patients received either a placebo or a 120 mg or 80 mg dose of MDMA. Once the treatment was administered, the patients were given headphones to listen to music and eye masks to wear while they sat with the researchers to observe how they reacted.

Once two hours had elapsed, the researchers administered an additional booster dose of between 40 to 60 mg, after which the patients went for 90-minute therapy sessions to discuss their experiences.

The trial’s results show that almost 90% of the participants experienced substantial improvements in their symptoms following their third therapy session. Another 67% also noted that there was so much progress that they no longer experienced symptoms that would warrant a post-traumatic stress-disorder diagnosis.

The researchers also observed a separate control group that did not receive MDMA but did receive counseling. They found that of the total number of participants in that group, one-third were cured of their symptoms of PTSD over the same period of time.

In their report, the researchers revealed that they planned to begin the process for obtaining drug approval from the FDA, noting that they planned to file a New Drug Application in the third quarter of 2023. The Food and Drug Administration may take roughly six months to approve or reject the application.

If the drug is approved by 2024, we could see MDMA being administered to millions of adults who suffer from post-traumatic stress disorder. At the moment, however, MDMA is classified as a Schedule I drug under the Controlled Substances Act. Drugs under this classification are not accepted for use in treatment in the United States and are believed to have a high potential for abuse.

If these drugs hit the market, psychedelic startups such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are likely to attract a lot more investor interest given the upward potential that approved drugs present.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer


Delic Holdings Corp (DELCF) Stock Research Links

DELCF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 23

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 63

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading